Biological Immunology

Dupixent

Payments companies reported to CMS as associated with Dupixent. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$120Massociated payments (2023-2025)

71,505clinicians with associated payments

6companies reporting

By year

2023 $33M

2024 $40M

2025 $47M

Payments reported as associated with Dupixent, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Dermatology $34M

Pulmonary Disease $14M

Allergy & Immunology $14M

Gastroenterology (Internal Medicine) $9.6M

Otolaryngology $7.3M

Physician Assistant $6.8M

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Dupixent

These are the largest totals companies reported as associated with Dupixent. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Cedric Franklin Rutland	Riverside, CA	Critical Care Medicine (Internal Medicine)	$848,489.78
Alexandra Golant	New York, NY	Dermatology	$835,964.98
Marcjonathan Serota	Littleton, CO	Dermatology	$765,666.16
Jonathan Silverberg	Washington, DC	Dermatology	$758,100.95
Benjamin Lockshin	Silver Spring, MD	Dermatology	$740,479.05
David Yen	Bethlehem, PA		$736,508.33
Elizabeth Swanson	Meridian, ID	Pediatric Dermatology	$719,651.65
Douglas Kress	Wexford, PA	Dermatology	$705,777.36
Nicole Chase	Saint Paul, MN	Allergy & Immunology	$703,865.56
Pearl Kwong	Jacksonville, FL	Pediatric Dermatology	$703,823.74

Prescribed Dupixent?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.